Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Metrics to compare | ACTI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACTIPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.3x | −6.7x | −0.5x | |
PEG Ratio | −0.11 | −0.08 | 0.00 | |
Price/Book | 11.6x | 3.7x | 2.6x | |
Price / LTM Sales | - | 41.3x | 3.3x | |
Upside (Analyst Target) | 139.2% | 20.3% | 43.5% | |
Fair Value Upside | Unlock | 10.4% | 6.3% | Unlock |